Please login to the form below

What everyone forgets about good organisational change in pharma

Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account.

When an organisation undergoes significant change, it can be make or break. On the one hand, if the company gets it wrong, it could end up with a toxic culture, high staff turnover rate and a loss of the company’s original mission – not to mention falling revenue.

On the other hand, when done well, an organisation could find itself better able to capture new opportunities, excite and galvanise employees and bring in new financial gains. If it fails to change at all, it could face a fate like that of Woolworths or Blockbuster – relegated to the history books.

In complex pharma markets there is often a greater need to be agile and reposition as the landscape transforms with the onset of new technology, diverse stakeholder relationships and competitor activities.

At some point, most companies will review the way they operate and find room for improvement. This could lead to small incremental changes or a full organisational transformation. Both require vision and sensitive execution, not to mention sparkling clarity in communications to stakeholders about why the change is taking place. However, these ‘softer’ steps are often overlooked, delaying the project and leading to higher costs.

Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account.

What’s the top challenge pharma companies face when it comes to organisational transformation?

DC: We are in the thick of embracing digital opportunities to reach customers, shifting from product focus to customer focus As a result, multichannel is shaking up pharma companies to the core. They must examine how well they really understand their customers, their mechanisms for building and deriving value from customer insight, and their strengths and weaknesses in non-sales-rep channels.

At BLH, we talk a lot about People, Process and Platforms as key facets of organisational change, and multichannel transformation truly touches all three. There is a need for holistic assessment and strategic design of any multichannel transformation endeavour.

Do pharma marketers need to evolve their skills sets to keep up with changes like multichannel marketing?

They do, but to really gain buy-in, it’s important to build the appropriate communication and motivation. Often this proves challenging for our clients. Training doesn’t just convey new material, it should also support learners in embedding the information into their daily working lives. Marketers are subject to a regular onslaught of training and development in different, but only have 1% of the working week to focus on these opportunities. They need to know the real value and benefit and to be able to learn in an efficient and effective manner.

Download the full article from Blue Latitude Health

6th December 2018

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need
Blue Latitude Health
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need.
Blue Latitude Health
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence.
Blue Latitude Health
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry.
Blue Latitude Health
Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget.
Blue Latitude Health
Innovative approaches in the treatment of multiple sclerosis
Blue Latitude Health Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon.
Blue Latitude Health